COMPANY PROFILE

Orthox

Explore full profile

Developes tissue regenerative implants which enable patients to return to a fully active, pain-free lifestyle

Milton, United KingdomFounded 2008Biotech & Life Sciences

Valuation $50–100M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Orthox

Orthox is a pioneering company in the life sciences sector, focusing on innovative solutions for knee injuries. The company operates in the medical technology market, specifically targeting patients with cartilage and meniscus injuries in the knee. These injuries can lead to severe disability and often result in the need for total knee replacement, a costly and invasive procedure. Orthox aims to provide a less invasive alternative through its lead product, Cartilage, a natural implant designed to restore knee function and promote the body's own healing processes.

Orthox primarily serves patients who are at risk of or are already experiencing knee joint deterioration. This includes both young and older individuals who suffer from knee injuries that could lead to osteoarthritis. The company's products are particularly beneficial for those who want to avoid the limitations and risks associated with total knee replacement surgery.

The business model of Orthox revolves around the development, clinical testing, and eventual commercialization of its knee cartilage repair products. The company has secured significant funding from various prestigious sources, including the EU Horizon 2020 programme and the NIHR i4i programme. These funds are being used to advance the clinical strategy and bring their innovative solutions to market.

Orthox generates revenue through the sale of its medical implants once they pass clinical trials and receive regulatory approval. The company also benefits from grants and awards that support its research and development activities. By focusing on a niche but growing market, Orthox aims to address a critical medical need and reduce the number of total knee replacement surgeries performed annually.

In summary, Orthox is a forward-thinking company dedicated to improving knee health through natural, resilient implants that restore function and promote healing. Their innovative approach and strong financial backing position them well in the competitive medical technology market.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2008
Headquarters: Milton, United Kingdom
Employees: 9
Open positions: None listed
Dealroom signal: 58.9/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Developer Tools, medical implants, Tissue Engineering, Spinout, Sustainable Development Goals, EIC, Start-Up Rescue Instrument (EIT Health), Start-Up Rescue Instrument 2020 (EIT Health)
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Aug 2022	$13M	$50M	Oxford Technology · Additio Investment Group · Parkwalk Advisors	↗
SERIES A✓Equity / VC	Feb 2022	$4.2M	$17M	Parkwalk Advisors · Oxford Technology · Perivoli Innovations · Additio Investment Group	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Margin	Margin
2026	—	—
2025	—	—
2024	—	—
2023	—	—
2022	—	—
2021	—	—
2020	—	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Orthox website traffic

Latest recorded traffic for Orthox is 3.3K monthly website visits, up 153.8% over the last three months. Orthox's team grew 0% over the past year.

Latest monthly visits3.3K 3-month web change+153.8% 1-year team growth0%

Monthly website visitsJul 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OEOxford EndovascularOrigami-inspired flow diverter for treating brain aneurysms	Oxford, United Kingdom	Operational	9	$24M	$42M
LMLattice MedicalLattice Medical develops MATTISSE, a fully degradable 3D printed breast implant for natural, uncomplicated breast restoration	Loos, France	Operational
ILiLoFAI and photonics platform for personalized drug discovery.	London, United Kingdom	Operational
IPIlya PharmaIlya Pharma develops immune-cell therapies. The company's biological medicine uses lactic acid bacteria as vectors to deliver biological drugs on-site to skin wounds or the GI tract	Uppsala kommun, Sweden	Operational
MEMedisieveMagnetic blood filtration enhancing gene therapy efficacy.	London, United Kingdom	Operational
VMVolumina MedicalDevelops injectable 3D scaffolds for the reconstruction of volumes of soft tissues	Epalinges, Switzerland	Operational
SPSpyBiotechNovel vaccine platform using protein superglue technology	Oxford, United Kingdom	Operational
LMLymphatica MedtechA minimally invasive implant and a discrete wearable device designed to re-establish the lymphatic circulation	Lausanne, Switzerland	Operational